Osimertinib Drugs Market Report 2026

Osimertinib Drugs Market Overview

• Osimertinib Drugs market size has reached to $7.75 billion in 2025 • Expected to grow to $16.25 billion in 2030 at a compound annual growth rate (CAGR) of 16.1% • Growth Driver: Increasing Incidence Of Lung Cancer Boost The Demand For Osimertinib Drug • Market Trend: AstraZeneca Launches Osimertinib: A New Hope for Patients with Unresectable NSCLC • North America was the largest region in 2025.

What Is Covered Under Osimertinib Drugs Market?

Osimertinib is a medication used to treat non-small cell lung cancer (NSCLC) in patients with particular abnormal epidermal growth factor (EGFR) genes. It is a kinase inhibitor and works by blocking the action of the abnormal protein that signals cancer cells to multiply. The main types of osimertinib drugs are 40mg and 80 mg. 40mg refers to the dosage strength of the Osimertinib tablet. They are distributed through various channels including hospital pharmacies, drugstores, retail pharmacies, and online pharmacies, for locally advanced non-small cell lung cancer (NSCLC), metastatic non-small cell lung cancer (NSCLC), and others.

What Is The Osimertinib Drugs Market Growth Forecast?

The osimertinib drugs market size is expected to see rapid growth in the next few years. It will grow to $16.25 billion in 2030 at a compound annual growth rate (CAGR) of 16.1%. The growth in the forecast period can be attributed to expansion of precision oncology programs, increasing diagnosis rates in emerging economies, development of next-generation egfr inhibitors, broader reimbursement coverage, ongoing clinical trials for new indications. Major trends in the forecast period include expanded use as first-line egfr therapy, rising adoption in metastatic nsclc treatment, growing preference for oral targeted therapies, increasing combination therapy research, improved patient compliance through once-daily dosing.

Global Osimertinib Drugs Market Segmentation

1) By Type: 40 mg, 80 mg 2) By Distribution Channel: Hospital Pharmacy, Drug Store And Retail Pharmacy, Online Pharmacy 3) By Application: Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Other Applications Subsegments: 1) By 40 mg: Maintenance Therapy in Tolerability-Sensitive Patients, Dose Adjustment for Drug–Drug Interactions 2) By 80 mg: First-Line Treatment for EGFR-Mutated NSCLC, Second-Line Treatment for T790M-Positive NSCLC

What Are The Drivers Of The Osimertinib Drugs Market?

The increasing incidence of lung cancer is expected to propel the growth of the osimertinib drug market going forward. Lung cancer refers to a type of cancer that originates in the lung tissues, predominantly in the cells lining the airways. Osimertinib is used as a therapeutic option for lung cancer, and it helps to block the activity of specific proteins that are involved in the growth and spread of cancer cells. For instance, in January 2023, according to the American Cancer Society Facts and Figures, a US-based professional organizations company, the estimated number of new lung and bronchus cancer cases was 236,740 in 2022 and 238,340 in 2023, while the estimated deaths were 130,180 in 2022 and 127,070 in 2023. Therefore, the increasing incidence of lung cancer is driving the growth of the osimertinib drug industry. The increasing initiatives from organizations to improve lung cancer care and treatment are expected to propel the growth of the osimertinib drug market going forward. Organizational initiatives to enhance lung cancer care and treatment involve policies, funding, and programs implemented by the organizations to improve the accessibility, affordability, and quality of care for individuals diagnosed with cancer. Organizations have launched initiatives to enhance lung cancer care, focusing on optimizing the utilization of the drug osimertinib for more effective treatment. For instance, in May 2024, The Australian Department of Health and Aged Care, an Australia-based government agency implemented National Lung Cancer Screening Program (NLCSP). This aims to implement a structured approach to early detection of lung cancer using low-dose computed tomography (LDCT) scans. This initiative is designed to target high-risk individuals, particularly those aged 50 to 80 with a significant smoking history. Therefore, the increasing initiatives from organizations to improve lung cancer care and treatment are driving the growth of the osimertinib drug industry.

Key Players In The Global Osimertinib Drugs Market

Major companies operating in the osimertinib drugs market are AstraZeneca plc, Dr. Reddy's Laboratories Ltd., Cipla Limited, Zydus Lifesciences Limited, Sun Pharmaceutical Industries Ltd., Alembic Pharmaceuticals Limited, Aristo Pharmaceuticals Private Limited, Incepta Pharmaceuticals Ltd., Beacon Pharmaceutical Limited, Drug International Limited, MSN Laboratories Pvt Ltd., Hetero Drugs Ltd., Accord Healthcare Limited, Dolphin Pharmaceutical Limited, Radiant Pharmaceuticals Ltd., Beximco Pharmaceuticals Ltd., Eskayef Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Natco Pharma Limited, Alkem Laboratories Ltd.

Global Osimertinib Drugs Market Trends and Insights

Major companies operating in the osimertinib drugs market are focusing on targeted therapies to improve outcomes for patients with non-small cell lung cancer (NSCLC), particularly those with EGFR mutations, aiming to enhance treatment effectiveness and patient quality of life. These companies are also investing in clinical trials and research collaborations to expand osimertinib's indications and explore its efficacy in combination with other therapies for broader patient benefits. For instance, in September 2024, AstraZeneca Pharmaceuticals LP, a US-based pharmaceutical company, launched osimertinib (Tagrisso) for adults with locally advanced, unresectable non-small cell lung cancer (NSCLC) with specific EGFR mutations approved by the FDA. This approval follows a clinical trial demonstrating significant improvements in progression-free survival compared to placebo.

Regional Insights

North America was the largest region in the osimertinib drugs market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Osimertinib Drugs Market?

The osimertinib drugs market consists of sales of tagrisso, osi-TKI, and osimertinib mesylate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Osimertinib Drugs Market Report 2026?

The osimertinib drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the osimertinib drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.